Skip to content

hypoxia-inducible factor-1 alpha is a key regulator of angiogenesis and inflammation in rheumatoid arthritis: a case-control study

hypoxia-inducible factor-1 alpha is a key regulator of angiogenesis and inflammation in rheumatoid arthritis: a case-control study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026471
Enrollment
Unknown
Registered
2019-10-11
Start date
2019-10-07
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Sponsors

Shanghai Traditional Medicine University Affiliated Guanghua Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: Criteria for RA: (1) patients with definite diagnosis of rheumatoid arthritis; (2) patients have no serious primary diseases, chronic wasting diseases and mental disorders such as cardiac, cerebrovascular, liver, kidney and hematopoietic system; (3) patients with knee joint pain accompanied by destruction need knee joint replacement; (4) patients have better compliance and can complete the whole course of treatment.

Exclusion criteria

Exclusion criteria: (1) the patients refused to undergo knee replacement; (2) the patients have surgical contraindications; (3) those with poor compliance or who are participating in other drug trials; (4) patients who have not been treated with this test protocol as required.

Design outcomes

Primary

MeasureTime frame
HIF-1 alpha;INOS;VEGFA;

Countries

China

Contacts

Public ContactXiao Lianbo
13701888178@163.com021-62805833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026